Novartis Inks $3.2B Deal for Alteogen's Drug Delivery Tech Used in Merck's Keytruda
MRK sits 93% above its 52-week low of $77.58.
Summary
Novartis signed a deal worth up to $3.22 billion with Alteogen for its Hybrozyme technology, which enables injectable versions of IV drugs. The technology is already used in Merck's Keytruda Qlex, approved last year. This is Alteogen's fourth licensing deal this year, highlighting growing industry demand for subcutaneous drug delivery. For Merck, the deal validates the technology behind its Keytruda Qlex but does not directly change its financials or pipeline. The news is a positive read-through for Merck's competitive positioning in the injectable oncology space, though the direct impact is limited.
At the time of this announcement, MRK was trading at $150.01 on NYSE in the Life Sciences sector, with a market capitalization of approximately $369.7B. The 52-week trading range was $77.58 to $156.92. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: Reuters.